Showing 3001-3020 of 8668 for: Cochrane Systematic Reviews Back
- Gloves, extra gloves or special types of gloves for preventing percutaneous exposure injuries in healthcare personnel
Cochrane Systematic Reviews, 7-Mar-2014
Healthcare workers are at risk of acquiring viral diseases such as hepatitis B, hepatitis C and HIV through exposure to contaminated blood and body fluids at work. Most often infection occurs when a healthcare worker inadvertently punctures the skin of th
- Gloves, gowns and masks for reducing the transmission of meticillin‐resistant Staphylococcus aureus (MRSA) in the hospital setting
Cochrane Systematic Reviews, 16-Jul-2015
Meticillin-resistant Staphylococcus aureus (MRSA; also known as methicillin-resistant S aureus) is a common hospital-acquired pathogen that increases morbidity, mortality, and healthcare costs. Its control continues to be an unresolved issue in many hospi
- GLP‐1 receptor agonists for Parkinson's disease
Cochrane Systematic Reviews, 23-Jul-2020
Parkinson's disease (PD) is a progressive disorder characterised by both motor and non-motor problems. Glucagon-like peptide-1 (GLP-1) receptor agonists, licensed for treatment of type 2 diabetes, work by stimulating GLP-1 receptors in the pancreas, which
- Glucagon-like peptide analogues for type 2 diabetes mellitus
Cochrane Systematic Reviews, 23-Jul-2013
Glucagon-like peptide analogues are a new class of drugs used in the treatment of type 2 diabetes that mimic the endogenous hormone glucagon-like peptide 1 (GLP-1). GLP-1 is an incretin, a gastrointestinal hormone that is released into the circulation in
- Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia
Cochrane Systematic Reviews, 19-Mar-2020
Congenital adrenal hyperplasia (CAH) is an autosomal recessive condition which leads to glucocorticoid deficiency and is the most common cause of adrenal insufficiency in children. In over 90% of cases, 21-hydroxylase enzyme deficiency is found which is c
- Glucocorticoid supplementation during ovarian stimulation for IVF or ICSI
Cochrane Systematic Reviews, 27-Mar-2017
Ovarian response to stimulation during in-vitro fertilisation (IVF) and intra-cytoplasmic sperm injection (ICSI) plays an important role in determining live birth rates. Adjuvant treatments during ovarian stimulation that have different modes of action ha
- Glucocorticoid with cyclophosphamide for oral paraquat poisoning
Cochrane Systematic Reviews, 30-Jun-2021
This an update of a Cochrane Review.
- Glucocorticoids for acute viral bronchiolitis in infants and young children
Cochrane Systematic Reviews, 4-Jun-2013
Previous systematic reviews have not shown clear benefit of glucocorticoids for acute viral bronchiolitis, but their use remains considerable. Recent large trials add substantially to current evidence and suggest novel glucocorticoid-including treatment a
- Glucocorticoids for croup in children
Cochrane Systematic Reviews, 22-Aug-2018
Glucocorticoids are commonly used for croup in children. This is an update of a Cochrane Review published in 1999 and previously updated in 2004 and 2011.
- Glucocorticoids for the treatment of anaphylaxis
Cochrane Systematic Reviews, 18-Apr-2012
Anaphylaxis is a serious hypersensitivity reaction that is rapid in onset and may result in death. Anaphylaxis guidelines recommend glucocorticoids for the treatment of people experiencing anaphylaxis.
- Glucocorticosteroid‐free versus glucocorticosteroid‐containing immunosuppression for liver transplanted patients
Cochrane Systematic Reviews, 9-Apr-2018
Liver transplantation is an established treatment option for end-stage liver failure. Now that newer, more potent immunosuppressants have been developed, glucocorticosteroids may no longer be needed and their removal may prevent adverse effects.
- Glucocorticosteroids for infants with biliary atresia following Kasai portoenterostomy
Cochrane Systematic Reviews, 14-May-2018
Biliary atresia is a life-threatening disease characterised by progressive destruction of both intra- and extra-hepatic biliary ducts. The mainstay of treatment is Kasai portoenterostomy, as soon as the disease has been confirmed. Glucocorticosteroids are
- Glucocorticosteroids for people with alcoholic hepatitis
Cochrane Systematic Reviews, 9-Apr-2019
Alcoholic hepatitis is a form of alcoholic liver disease characterised by steatosis, necroinflammation, fibrosis, and complications to the liver. Typically, alcoholic hepatitis presents in people between 40 and 50 years of age. Alcoholic hepatitis can be
- Glucocorticosteroids for primary biliary cirrhosis
Cochrane Systematic Reviews, 20-Apr-2005
Primary biliary cirrhosis is a chronic progressive cholestatic liver disease of presumed autoimmune etiology, characterised by the destruction of small intrahepatic bile ducts and the eventual development of cirrhosis and liver failure. Its progression ma
- Glucocorticosteroids for primary sclerosing cholangitis
Cochrane Systematic Reviews, 20-Jan-2010
Primary sclerosing cholangitis is a chronic cholestatic disease of intrahepatic and extrahepatic biliary ducts, characterised by chronic periductal inflammation and sclerosis of the ducts, which results in segmental stenoses of bile ducts, cholestasis, fi
- Glucocorticosteroids for viral hepatitis C
Cochrane Systematic Reviews, 19-Apr-2004
Hepatitis C virus may cause liver inflammation and fibrosis. It is not known whether glucocorticosteroids are beneficial or harmful for patients with hepatitis C infection.
- Glucosamine therapy for treating osteoarthritis
Cochrane Systematic Reviews, 20-Apr-2005
Osteoarthritis (OA) is a common form of arthritis and is often associated with significant disability and impaired quality of life. This is an update of a Cochrane review first published in 2001 and previously updated in 2005.
- Glucose targets for preventing diabetic kidney disease and its progression
Cochrane Systematic Reviews, 8-Jun-2017
Diabetes is the leading cause of end-stage kidney disease (ESKD) around the world. Blood pressure lowering and glucose control are used to reduce diabetes-associated disability including kidney failure. However there is a lack of an overall evidence summa
- Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients
Cochrane Systematic Reviews, 30-Jul-2020
Kidney transplantation is the preferred management for patients with end-stage kidney disease (ESKD). However, it is often complicated by worsening or new-onset diabetes. The safety and efficacy of glucose-lowering agents after kidney transplantation is l
- Glutamatergic drugs for schizophrenia
Cochrane Systematic Reviews, 31-Jan-2013
It has been shown that central nervous system dopamine can play a major role in the pathophysiology of schizophrenia. Brain glutamate is thought to mediate symptoms in schizophrenia due to the influence of glutamate neurons on the dopaminergic transmissio
